Although it should be recognized that SIK2 inhibitors have preclinically proven effective against several SIK2‐proficient cancers, a therapeutic approach directed at enhancing the level or functional activity of SIK2 may represent another important strategy for treatment of SIK2‐deficient cancer types such as GC, where SIK2 serves as a tumor suppressor. The gene discussed is SIK2; the disease is neoplasm.